Dr. Lee on Combining Anti-PD-L1 to Standard of Care for Head and Neck Cancer

Nancy Y. Lee, MD
Published: Monday, Jun 19, 2017



Nancy Y. Lee, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the combination of a PD-L1 inhibitor to the standard of care for patients with head and neck cancer.

In patients with HPV-negative head and neck cancer, local regional control is in the order of 50% to 70%, explains Lee. For HPV-positive head and neck cancer, the T4 N2c, which are the worse-comers, the local regional control is also around 60% to 70%.

According to Lee, by adding a PD-L1 inhibitor to the standard of care it will perhaps enhance the effect of local regional control.
 


Nancy Y. Lee, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the combination of a PD-L1 inhibitor to the standard of care for patients with head and neck cancer.

In patients with HPV-negative head and neck cancer, local regional control is in the order of 50% to 70%, explains Lee. For HPV-positive head and neck cancer, the T4 N2c, which are the worse-comers, the local regional control is also around 60% to 70%.

According to Lee, by adding a PD-L1 inhibitor to the standard of care it will perhaps enhance the effect of local regional control.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x